Shanea Leven, Founder and CEO at Empromptu AI, is a veteran product leader with extensive experience building developer platforms and AI-driven products at major technology companies. Prior to ...

These 12 Gemini prompts can help job seekers research roles, tailor applications, prepare for interviews, and negotiate offers more strategically.

There's one job interview question that you can almost guarantee hiring managers will ask that many people still struggle to answer. That's because there really is no clear angle. Still, if you're ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...

Four New York Times reporters pressed Mr. Trump about a range of topics in a nearly two-hour interview. Here is a transcript of their conversation. President Trump spoke to four New York Times ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

The Florida Python Challenge is arguably the most well-known and well-attended snake hunt in the country. And according to the results released Wednesday, the 2025 Challenge that took place in July ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...